Items where Author is "Baines, Simon D."

Item Type No Grouping

Article

Non-Toxigenic Clostridioides difficile Strain E4 (NTCD-E4) Prevents Establishment of Primary C. difficile Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model. (2023) Perezimor Etifa, César Rodríguez, Céline Harmanus, Ingrid M. J. G. Sanders, Igor A. Sidorov, Olufunmilayo A. Mohammed, Emily Savage, Andrew R. Timms, Jane Freeman, Wiep Klaas Smits, Mark H. Wilcox and Simon D. Baines

Antimicrobial resistance and reduced susceptibility in Clostridium difficile: potential consequences for induction, treatment, and recurrence of C. difficile infection. (2015) Simon D. Baines and M. H. Wilcox

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. (2015) D. Corbett, A. Wise, S. Birchall, P. Warn, Simon D. Baines, G. Crowther, J. Freeman, C. H. Chilton, J. Vernon, M. H. Wilcox and R. J. Vickers

SMT19969 as a treatment for Clostridium difficile infection : an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. (2015) Simon D. Baines, G. S. Crowther, J. Freeman, S. Todhunter, R. Vickers and M. H. Wilcox

Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. (2014) Grace S. Crowther, Caroline H. Chilton, Sharie L. Todhunter, Scott Nicholson, Jane Freeman, Simon D. Baines and Mark H. Wilcox

Development and validation of a chemostat gut model to study both planktonic and biofilm modes of growth of Clostridium difficile and human microbiota. (2014) Grace S. Crowther, Caroline H. Chilton, Sharie L. Todhunter, Scott Nicholson, Jane Freeman, Simon D. Baines and Mark H. Wilcox

In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. (2013) C. H. Chilton, G. S. Crowther, Simon D. Baines, S. L. Todhunter, J. Freeman, H. H. Locher, A. Athanasiou and M. H. Wilcox

Short-term genome stability of serial Clostridium difficile ribotype 027 isolates in an experimental gut model and recurrent human disease. (2013) David W. Eyre, A. Sarah Walker, Jane Freeman, Simon D. Baines, Warren N. Fawley, Caroline H. Chilton, David Griffiths, Alison Vaughan, Derrick W. Crook, Tim E. A. Peto and Mark H. Wilcox

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. (2013) Grace S Crowther, Simon D. Baines, Sharie L Todhunter, Jane Freeman, Caroline H Chilton and Mark H Wilcox

Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. (2013) Simon D. Baines, Caroline H. Chilton, Grace S. Crowther, Sharie L. Todhunter, Jane Freeman and Mark H. Wilcox

Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. (2013) C. H. Chilton, J. Freeman, Simon D. Baines, G. S. Crowther, S. Nicholson and M. H. Wilcox

Mixed infection by Clostridium difficile in an in vitro model of the human gut. (2013) Simon D. Baines, Grace S. Crowther, Sharie L. Todhunter, Jane Freeman, Caroline H. Chilton, Warren N. Fawley and Mark H. Wilcox

Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. (2011) Simon D. Baines, Alan R. Noel, Grace S. Huscroft, Sharie L. Todhunter, Rachael O'Connor, Joanne K. Hobbs, Jane Freeman, Andy M. Lovering and M. H. Wilcox

Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. (2011) Jane Freeman, Simon D. Baines, Sharie L. Todhunter, Grace S. Huscroft and M. H. Wilcox

The changing epidemiology of Clostridium difficile infections. (2010) J. Freeman, M. P. Bauer, Simon D. Baines, J. Corver, W. N. Fawley, B. Goorhuis, E. J. Kuijper and M. H. Wilcox

Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. (2009) Simon D. Baines, Rachel O'Connor, Katie Saxton, Jane Freeman and M. H. Wilcox

Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. (2009) Sarah Underwood, Shuang Guan, Vinod Vijayasubhash, Simon D. Baines, Luke Graham, Richard J. Lewis, M. H. Wilcox and Keith Stephenson

Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. (2009) Katie Saxton, Simon D. Baines, Jane Freeman, Rachael O'Connor and M. H. Wilcox

Mecillinam : a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. (2009) Simon D. Baines, Rachael O'Connor, Grace Huscroft, Katie Saxton, Jane Freeman and Mark H Wilcox

Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. (2009) Simon D. Baines, Jane Freeman and M. H. Wilcox

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. (2008) Simon D. Baines, Rachael O'Connor, Katie Saxton, Jane Freeman and Mark H. Wilcox

Emergence of reduced susceptibility to metronidazole in Clostridium difficile. (2008) Simon D. Baines, Rachael O'Connor, Jane Freeman, Warren N Fawley, Celine Harmanus, Paola Mastrantonio, Ed J. Kuijper and M. H. Wilcox

In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. (2008) Rachael O'Connor, Simon D. Baines, Jane Freeman and Mark H. Wilcox

Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. (2007) Jane Freeman, Simon D. Baines, Katie Saxton and Mark H. Wilcox

Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. (2007) Warren N Fawley, Sarah Underwood, Jane Freeman, Simon D. Baines, Katie Saxton, Keith Stephenson, Robert C. Owens and M. H. Wilcox

Measurement of toxin production by Clostridium difficile. (2006) Jane Freeman, Warren Fawley, Simon D. Baines and Mark Wilcox

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. (2006) Simon D. Baines, Katie Saxton, Jane Freeman and Mark H. Wilcox

Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. (2005) Jane Freeman, Joanna Stott, Simon D. Baines, Warren N. Fawley and Mark H. Wilcox

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. (2005) Jane Freeman, Simon D. Baines, Daniela Jabes and Mark H. Wilcox

Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. (2005) Simon D. Baines, Jane Freeman and Mark H. Wilcox

Other

Efficacy of novel antimicrobial agent SMT-19969 (SMT) against simulated Clostridium difficile infection in an in vitro human gut model. (2011) Simon D. Baines, J. Freeman, Grace S. Huscroft, Sharie L. Todhunter, M. H. Wilcox and R. Vickers

SASP: targeted delivery to Gram-negative pathogens. (2011) H. Wang, K. Hatzixanthis, A. Barnard, R. Shah, E. Saveri, K. Pitts, D. Piwowarczyk, G. Patil, Simon D. Baines, A. Wilkinson and H. Fairhead

SMT19969 – a novel antibiotic for C. difficile : Clostridium difficile growth inhibition, spectrum of activity and resistance development. (2011) R. Vickers, J. Tinsley, R. Storer, F. Wilson, C. Dorgan, S. Wren, M. H. Wilcox, Simon D. Baines and J. Freeman

Short-term genomic stability of Clostridium difficile within patients and a gut model. (2011) D. W. Eyre, C. Ip, R. M. Harding, J. Freeman, Simon D. Baines, W. N. Fawley, S.D. Walker, D. W. Crook, T. E. A. Peto and M. H. Wilcox